Retrospective analyses of indices of pancreatic and liver fat accumulations were conducted in 22 type 2 diabetes outpatients who were receiving SGLT‐2 inhibitors for more than 12 weeks. This evidence concerns the gene SLC5A2 and type 2 diabetes mellitus.